Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IUC-001
- Development stage
- Preclinical
- Lead developer
- Imvax
- Modality
- Vaccines & Immunotherapeutics
01
Overview
IUC-001 is a personalized autologous cancer vaccine being developed by Imvax for the treatment of urothelial cancer (bladder cancer). The therapy is an autologous biologic-device combination product that utilizes whole tumor-derived antigens from the patient to stimulate a specific anti-tumor immune response. As part of Imvax's Gold-Standard Immunotherapy platform, IUC-001 represents a personalized approach to treating solid tumors by leveraging the patient's own immune system against their unique tumor profile. The product is currently in preclinical development stages, with ongoing studies evaluating its potential efficacy in bladder cancer patients.
Beyond the preview
Go deeper on IUC-001.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IUC-001.